Actuate to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 9, 2026
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and DaraxonrasibGlobeNewsWire · Sep 9, 2026
All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to BuyZacks Investment Research · Sep 2, 2026Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.20 | -$0.20 | Beat |
| May 14, 2026 | -$0.23 | -$0.24 | Miss |
| Mar 26, 2026 | -$0.24 | -$0.18 | Beat |
| Nov 13, 2025 | -$0.27 | -$0.25 | Beat |
| Aug 14, 2025 | -$0.19 | -$0.30 | Miss |
| May 15, 2025 | -$0.30 | -$0.32 | Miss |